Amgen has reported findings from a real-world study where Prolia (denosumab) injection demonstrated significant reduction in osteoporotic fracture risk in postmenopausal women compared to alendronate.

The observational, retrospective study has enrolled 478,651 postmenopausal women aged 66 or above who previously did not receive any osteoporosis treatment.

Out of the total, 89,115 patients were treated with Prolia and the remaining received oral alendronate, a bisphosphonate treatment.

The study demonstrated that relative risk of fracture across various fracture types were reduced in patients using Prolia.

Furthermore, greater reduction in major osteoporotic (MOP) fracture risk was observed in patients using Prolia for longer duration.

Amgen vice-president and General Medicine global medical therapeutic area head Jyothis George said: “Amgen has long been committed to reducing the impact of osteoporosis, an underdiagnosed and undertreated disease that increases the risk for bone loss and fracture for millions of post-menopausal women.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“May is Osteoporosis Awareness and Prevention Month, making this a great time to share these new data about Prolia and the important role it can play in reducing the risk of potentially life-altering fractures in these women at high risk for fracture.”

Prolia targeting RANK Ligand, an essential regulator of bone-removing cells, is approved for use in over 80 countries globally.

It is also indicated for increasing bone mass in men with osteoporosis and treating glucocorticoid-induced osteoporosis in men and women.